Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Status:
Completed
Trial end date:
2013-03-31
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe, Japan and North America. The aim of this
trial is to evaluate the safety and efficacy, including pharmacokinetics (the rate at which
the body eliminates the trial drug), of NNC-0156-0000-0009 (nonacog beta pegol) when used for
treatment and prophylaxis of bleeding episodes in patients with haemophilia B.